Optimizing the Risk-Benefit Balance of Thromboprophylaxis in Critically Ill Patients With Coronavirus Disease 2019
- PMID: 32706558
- PMCID: PMC7375185
- DOI: 10.1097/CCM.0000000000004509
Optimizing the Risk-Benefit Balance of Thromboprophylaxis in Critically Ill Patients With Coronavirus Disease 2019
Conflict of interest statement
Dr. Wautrecht received funding from Bayer and Bristol Meyer Squibb. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Comment in
-
The authors reply.Crit Care Med. 2020 Oct;48(10):e989-e990. doi: 10.1097/CCM.0000000000004530. Crit Care Med. 2020. PMID: 32931200 Free PMC article. No abstract available.
Comment on
-
Coagulopathy of Coronavirus Disease 2019.Crit Care Med. 2020 Sep;48(9):1358-1364. doi: 10.1097/CCM.0000000000004458. Crit Care Med. 2020. PMID: 32467443 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
